The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases
Open accessAbstract
Research on the use of biodegradable polymers for drug delivery has been ongoing since they were first used as bioresorbable surgical devices in the 1980s. For tissue engineering and drug delivery, biodegradable polymer poly-lactic-co-glycolic acid (PLGA) has shown enormous promise among all biomaterials. PLGA are a family of FDA-approved biodegradable polymers that are physically strong and highly biocompatible and have been extensively studied as delivery vehicles of drugs, proteins, and macromolecules such as DNA and RNA. PLGA has a wide range of erosion times and mechanical properties that can be modified. Many innovative platforms have been widely studied and created for the development of methods for the controlled delivery of PLGA. In this paper, the various manufacturing processes and characteristics that impact their breakdown and drug release are explored in depth. Besides different PLGA-based nanoparticles, preclinical and clinical applications for different diseases and the PLGA platform types and their scale-up issues will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wu, P., Zhou, Q., Zhu, H., Zhuang, Y., & Bao, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-06803-7 · Cited by 97 · cited 2×
“but also greatly minimize side effects [72].”
BackgroundRetractedPoly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816 · cited 3×
“As shown in Figure 1, due to the presence of ester linkages that are degraded by hydrolysis in aqueous environments, it is controlled by polymer chemistry, such as glycoside unit content, initial molecular weight (MW) [30–32], stereochemistry (d and l composition) [1], or end-group functionalization [33].”
BackgroundBiodegradable polymers as biomaterials
Nair, L. S., & Laurencin, C. T. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.017 · Cited by 4,416
An Overview of Poly(lactic-co-glycolic) Acid (PLGA)-Based Biomaterials for Bone Tissue Engineering
Gentile, P., Chiono, V., Carmagnola, I., & Hatton, P. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033640 · Cited by 1,593
Polymer microspheres for controlled drug release
Freiberg, S., & Zhu, X. X. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.04.013 · Cited by 1,336
Challenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
Pillai, O., & Panchagnula, R. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00227-1 · Cited by 710
PLGA–lecithin–PEG core–shell nanoparticles for controlled drug delivery
Chan, J. M., Zhang, L., Yuet, K. P., Liao, G., Rhee, J.-W., Langer, R., & Farokhzad, O. C. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.12.013 · Cited by 702
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
Stolz, D., Mkorombindo, T., Schumann, D. M., Agusti, A., Ash, S. Y., Bafadhel, M., Bai, C., Chalmers, J. D., Criner, G. J., Dharmage, S. C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01273-9 · Cited by 681
Cited by
Recent Applications of PLGA in Drug Delivery Systems
Yang, J., Zeng, H., Luo, Y., Chen, Y., Wang, M., Wu, C., & Hu, P. (2024) · Polymers · doi:10.3390/polym16182606 · Cited by 268
PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy
Kesharwani, P., Kumar, V., Goh, K. W., Gupta, G., Alsayari, A., Wahab, S., & Sahebkar, A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02410-x · Cited by 132
PLGA-Based Co-Delivery Nanoformulations: Overview, Strategies, and Recent Advances
Stevanović, M. M., Qian, K., Huang, L., & Vukomanović, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121613 · Cited by 42
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Metadata
- Authors
- Alsaab, H. O., Alharbi, F. D., Alhibs, A. S., Alanazi, N. B., Alshehri, B. Y., Saleh, M. A., Alshehri, F. S., Algarni, M. A., Almugaiteeb, T., Uddin, M. N., & Alzhrani, R. M.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-12-06
- Volume
- 14
- Issue
- 12
- Pages
- 2728
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W4311717363
- Cited by
- 289
- References
- 149
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases. https://app.cochat.ai/papers/10.3390/pharmaceutics14122728
- The paper
- Alsaab, H. O., Alharbi, F. D., Alhibs, A. S., Alanazi, N. B., Alshehri, B. Y., Saleh, M. A., Alshehri, F. S., Algarni, M. A., Almugaiteeb, T., Uddin, M. N., & Alzhrani, R. M. (2022). PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14122728
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.